FDA committees take steps to making Narcan available over the counter

On Wednesday, two FDA advisory committees unanimously voted in favor of Narcan nasal spray being made available as an over-the-counter emergency treatment for opioid overdose.
Specifically, the Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee voted 19-0 that the benefit-risk profile of Narcan (naloxone hydrochloride, Emergent BioSolutions) nasal spray is “supportive of its use as a nonprescription opioid reversal agent.”
If approved, it would become the first 4 mg naloxone nasal spray available OTC, according to a press

On Wednesday, two FDA advisory committees unanimously voted in favor of Narcan nasal spray being made available as an over-the-counter emergency treatment for opioid overdose.
Specifically, the Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee voted 19-0 that the benefit-risk profile of Narcan (naloxone hydrochloride, Emergent BioSolutions) nasal spray is “supportive of its use as a nonprescription opioid reversal agent.”
If approved, it would become the first 4 mg naloxone nasal spray available OTC, according to a press